Arcadia Biosciences, Inc. 8-K

What Happened

• Arcadia Biosciences, Inc. announced a private placement under a Purchase Agreement dated June 11, 2026 (closing June 12, 2026) to sell pre-funded warrants and two series of preferred investment options, generating approximately $4.0 million in gross proceeds. The investor bought pre-funded warrants exercisable into up to 3,883,496 common shares and Series A-1 and Series A-2 preferred investment options (each tied to up to 3,883,496 option shares) at a purchase price of $1.0299 per pre-funded warrant plus accompanying investment options.
• The filing also discloses a Registration Rights Agreement (described in the report) under which the company must file a resale registration statement to register the resale of the Option Shares and use best efforts to have it declared effective within specified SEC timelines.

Key Details

• Transaction dates: Purchase Agreement dated June 11, 2026; Closing Date June 12, 2026; Registration Rights Agreement referenced in the filing.
• Economics and securities:
  • Gross proceeds: ~ $4.0 million (before fees and expenses).
  • Purchase price: $1.0299 per pre-funded warrant plus accompanying investment options.
  • Pre-funded warrants: exercisable for up to 3,883,496 common shares at $0.0001 per share; immediately exercisable; no expiration until fully exercised.
  • Series A-1 options: $0.91 exercise price; exercisable only after stockholder approval (Company must call a meeting on or before 90 days after the Closing Date to seek approval); expire five years after stockholder approval.
  • Series A-2 options: $0.91 exercise price; exercisable immediately; expire 24 months after the effective date of the resale registration statement.
  • Placement agent (H.C. Wainwright): cash fee 7% of gross proceeds, management fee 1%, expense reimbursements (up to $50k legal, $25k non-accountable), plus placement-agent options for up to 271,845 shares at $1.2875 per share.
• Holder protections and mechanics: holders may be limited to beneficial ownership caps (4.99% default or 9.99% elected with 61 days’ notice); cashless exercise permitted if no effective registration; certain options permit cash settlement (Black‑Scholes value) in some fundamental transactions.
• Securities were issued in a private placement (unregistered sales as reported under Item 3.02), with registration rights to enable resale.

Why It Matters

• Capital and dilution: the transaction raises immediate capital (≈ $4M) to fund operations but creates potential dilution if warrants/options are exercised. Placement-agent fees reduce net proceeds.
• Liquidity and resale: the company agreed to file and use best efforts to get a resale registration statement effective, which would allow the investor to sell the underlying shares in the market once effective; until then, cashless exercise and ownership caps may limit immediate transferability.
• Governance/approval condition: Series A-1 options cannot be exercised until stockholder approval; the company must call a meeting within 90 days after closing (and every 90 days thereafter if not approved) — this timing can affect when shares tied to those options can be issued.
• Investor protections: ownership caps, cashless exercise provisions and cash‑settlement options on certain transactions limit investor control and provide defined outcomes in M&A scenarios.

(Press releases about the transaction were furnished as exhibits to the 8-K; the exhibits and definitive documents are available in the filing for more detail.)